Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology (Nasdaq: KURA) has appointed Teresa Bair as Chief Legal Officer and Corporate Secretary. Bair brings over 25 years of legal experience, recently serving as General Counsel at Athenex, where she assisted in multiple NDA filings and an FDA approval. Kura's President, Troy Wilson, emphasized her expertise in drug development, crucial for advancing their oncology drug pipeline. Kura focuses on precision medicines for cancer, with pipeline candidates like KO-539 and tipifarnib, which has gained Breakthrough Therapy Designation.
Kura Oncology (Nasdaq: KURA) announced that Troy Wilson, Ph.D., J.D., CEO, will participate in two virtual investor conferences. He will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with an on-demand recording available starting at 7:00 a.m. ET. Additionally, he will engage in a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 3:20 p.m. ET. Audio webcasts of both events will be accessible on Kura's website, with archived replays available after both events.
Kura Oncology reported its Q2 2021 results, highlighting key advancements in clinical trials and collaborations. The first patients have been dosed in the Phase 1b cohorts for KO-539, a menin inhibitor targeting relapsed/refractory AML. A collaboration with Novartis aims to assess tipifarnib with alpelisib in HNSCC. Kura has also nominated KO-2806 as its lead candidate in a new farnesyl transferase program. Financially, the company reported a net loss of $33.7 million with $567.5 million in cash reserves expected to sustain operations into 2024.
Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. CEO Troy Wilson will join a panel discussion titled “Bullseye - Targeted Oncology Part 2” at 10:20 a.m. ET. A live audio webcast will be accessible via the Investors section of Kura's website, with a replay available shortly after the event. Kura focuses on precision medicines for cancer, currently advancing drug candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancer types.
Kura Oncology, a clinical-stage biopharmaceutical company, will announce its second quarter 2021 financial results on August 5, 2021, after market close. A webcast and conference call will follow at 4:30 p.m. ET. The company is focused on precision medicines for cancer treatment, with several drug candidates including KO-539 for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma. Kura's therapies aim to target specific cancer pathways and improve patient outcomes.
Kura Oncology, Inc. (Nasdaq: KURA) announced the appointment of Dr. Helen Collins to its board of directors. Dr. Collins, a veteran in medical oncology with over 25 years of experience, previously served as Chief Medical Officer at Five Prime Therapeutics. Her expertise will be instrumental as Kura advances its pipeline, including the KO-539 menin inhibitor in acute myeloid leukemia and the tipifarnib program for HRAS mutant head and neck squamous cell carcinoma. This strategic addition aims to enhance Kura's clinical development efforts and fulfill its mission of precision cancer therapies.
Kura Oncology, Inc. announced a clinical collaboration with Novartis to study the combination of tipifarnib and alpelisib for treating head and neck squamous cell carcinoma (HNSCC) driven by HRAS or PIK3CA pathways. This follows promising preclinical results indicating enhanced anti-tumor activity when both drugs target co-dependent pathways. The Phase 1/2 KURRENT trial is set to commence in the second half of 2021, aiming to potentially broaden tipifarnib's application among advanced HNSCC patients. Kura retains global rights to tipifarnib.
Kura Oncology announced the dosing of the first patient in the Phase 1b expansion of KOMET-001, targeting relapsed/refractory acute myeloid leukemia (AML) with its selective menin inhibitor, KO-539. The trial includes two cohorts: 200 mg and 600 mg doses, each enrolling at least 12 genetically enriched patients. KO-539 showed promising activity and a favorable safety profile in prior phases. The data obtained will aid in determining the recommended Phase 2 dose and potentially contribute to registration efforts. Kura aims to present future data at medical meetings.
Kura Oncology (Nasdaq: KURA) announced its participation in the JMP Securities Life Sciences Conference, with CEO Troy Wilson scheduled for a virtual presentation on June 17, 2021, at 3:00 p.m. ET. The live audio webcast will be accessible on Kura's website, with a replay available afterward. Kura focuses on precision medicines for cancer treatment, with promising candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancers, including acute myeloid leukemia and HRAS mutant head and neck cancer.
Kura Oncology (Nasdaq: KURA) announced the appointment of Carol Schafer to its board of directors, effective June 3, 2021. With over 25 years of experience in healthcare investment banking, including her recent role as Vice Chair of Equity Capital Markets at Wells Fargo Securities, Schafer is expected to contribute significantly to Kura’s strategic initiatives. She will succeed Robert Hoffman, who is stepping down from the board on August 3, 2021, after six years of service. Kura's pipeline includes promising cancer treatment candidates like KO-539 and Tipifarnib.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
